EGFR status and expression of downstream kinases in colorectal tumors and metastatic sites
This article has no abstract so we have provided the first paragraph of the full text.
Investigations have shown that EGFR status is not predictive of success with anti-EGFR therapies in colorectal cancer. Scartozzi et al. studied EGFR status and expression of the EGFR downstream kinases phosphorylated Akt and MAPK in primary colorectal tumors and their corresponding metastatic sites in order to define the EGFR-regulated molecular profile that would aid treatment selection.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.